Multiple buying at RepliCel Life Sciences (V:RP)

David M. Hall, CEO and Director, acquired 77,398 Common Shares on a direct ownership basis at a price of $0.475 through a prospectus or prospectus exempt offering on January 15th, 2019. This represents a $36,764 investment into the company's shares and an account share holdings change of 44.5%.

On the same terms, Geoffrey MacKay, a Director, acquired 58,325 Common Shares on a direct ownership basis at a price of $0.475. This represents a $27,704 investment into the company's shares and an account share holdings change of greater than 100%. Kevin McElwee, a 10% Holder, acquired 55,263 Common Shares on an indirect ownership basis for registered holder McElwee Consulting Inc. This represents a $26,250 investment into the company's shares and an account share holdings change of 13.0%.

Peter Winston Lewis, a Director, acquired 35,789 Common Shares on a direct ownership basis at a price of $0.475 through a prospectus or prospectus exempt offering on January 15th, 2019. This represents a $17,000 investment into the company's shares and an account share holdings change of greater than 100%.

RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration